Multiple system atrophy (MSA) is an adult-onset sporadic neurodegenerative disorder of unknown etiology featuring parkinsonism, ataxia, and autonomic failure in any combination. Because disease progression in MSA is rapid and no drug treatment consistently benefits MSA patients in the long term, neuroprotective or regenerative strategies may be invaluable in the management of MSA patients. In this study, we investigated whether human mesenchymal stem cells (hMSCs) had a protective effect on MSA using an animal model of double-toxin-induced MSA parkinsonism (MSA-P). MSA-P was established with coinjections of MPTP and 3-NP; hMSCs were injected into the tail vein 1 day after the last toxin injection. Three groups of mice were compared (i.e., control, MPTP + 3-NP, and MPTP + 3-NP with hMSC treatment) through histopathological, behavioral, and Western blot analyses. In the substantia nigra (SN) and the striatum, 2.0% and 3.8% of total injected hMSCs were observed, respectively. Compared with double-toxin-treated mice, hMSC treatment in double-toxin-treated mice significantly increased survival of TH-and NeuN-immunoreactive cells in the SN and the striatum, with coincident improvement in motor behavior. Additionally, hMSC treatment significantly decreased double-toxin-induced microglial and astroglial activation in the SN and striatum. Western blot analysis showed that hMSC administration in double-toxin-treated mice increased the expression of p-Akt and Bcl-2 and decreased Bax and cytochrome c expression. This study demonstrates that hMSC treatment protected against loss of neurons in the SN and the striatum induced by double toxin exposure, which may be mediated by modulation of inflammatory and cell survival and death signalingpathway as the hMSCs migrated from the peripheral circulation into the SN and striatum.
INTRODUCTION
MSA. Among those, Stefanova et al. (23) demonstrated that MAO-B inhibitor had a disease-modifying activity in transgenic animal model of MSA. However, other Multiple system atrophy (MSA) is a sporadic neurodegenerative disease of the central and autonomic ner-clinical trials have failed to delay disease progression. Mesenchymal stem cells (MSCs) are present in adult vous system. Pathologically, MSA includes striatonigral degeneration, olivopontocerebellar degeneration, astro-bone marrow and represent <0.01% of all nucleated bone marrow cells. MSCs are themselves capable of gliosis, and microgliosis. Clinically, cardinal features include autonomic failure, parkinsonism (MSA-P), cere-multipotency, with differentiation under appropriate conditions into chondrocytes, skeletal myocytes, and bellar ataxia, and pyramidal signs in any combination, of which autonomic failure is an integral component in neurons (16, 21, 32) . MSCs secrete various cytotrophic factors that, in turn, exert neuroprotective effects (3). the diagnosis of MSA (29). MSA is regarded as a unique entity within the spectrum of oligodendrogliopathy, with
Our previous study in both in vitro and animal model of Parkinson's disease using a proteasome inhibitor dem-α-synuclein-positive glial cytoplasmic inclusions (GCI) being a pathological hallmark (30). Because the progno-onstrated that human MSCs (hMSCs) had a protective effect on progressive dopaminergic neuronal loss through sis of MSA is fatal, many in vivo and clinical trials have been conducted to archive neuroprotective strategies in a variety of mechanisms, such as antiapoptotic effects, 828 PARK ET AL. modulation of polyubiquitinated proteins, and anti-inflam-Irvine, CA, USA) and 1% penicillin/streptomycin (P/S; Sigma, St. Louis, MO, USA) in a humidified incubator matory actions in addition to possible transdifferentiating effect of hMSCs into dopaminergic neurons (20) . maintained at 37°C with 5% CO 2 . Nonadherent cells were removed after 24 h. When the primary cultures Furthermore, we recently reported an open-label clinical trial of hMSCs in patients with MSA, which demon-reached 80% confluence, cells were harvested using 0.25% trypsin and subcultured. At passage 6, hMSCs strated that hMSC injection delayed progression of neurological deficits and improved cerebral glucose metab-were injected into mice via tail vain. olism in cerebellum compared with untreated patients Behavioral Test (14) .
The animal model of MSA-P is based on the concept The pole test was performed according to a previous study (17) . Each mouse was placed on the top of a verti-of inducing selective degeneration in nigral and striatal neurons by using 1-methyl-4-phenyl-1,2,3,6 tetrahydro-cal wooden rough-surfaced pole (1-cm diameter; 50-cm height). On the day prior to testing, mice were habitu-pyridine (MPTP) and 3-nitropropionic acid (3-NP), which were previously used to mimic Parkinson's dis-ated to the apparatus by placing them at the top of the pole and allowing them to descend five times. The total ease and Huntington's disease, respectively, in rodents (24) . In this double lesion model, the MPTP is known time that it took each mouse to reach the base of the pole and place all four paws on the floor was recorded. to potentiate striatal damage and behavioral impairments induced by 3-NP intoxication and thus constitute a use-For each session of five descents, the best performance was recorded as the total time. If the mouse was unable ful model of MSA-P. In the present study, we investigated whether hMSCs had a protective effect against to turn completely downward, fell off, or slipped down the pole, a default value of 120 s was recorded. The pole neuronal loss in the substantia nigra (SN) and striatum using double-toxin-induced animal model of MSA-P.
test was performed at baseline, then at days 2, 4, 6, and 8 during double toxin injection and at days 1, 10, and MATERIALS AND METHODS 20 after hMSC administration.
Animal Study
Tissue Preparation In total, 34 male C57BL/6 mice (16 weeks old) were For immunohisotochemistry, mice were perfused used. Animals were divided into three groups: controls, with a saline solution containing 0.5% sodium nitrate MPTP + 3-NP-treated group, and hMSCs group (MPTP and heparin (10 U/ml) and were fixed with 4% para-+ 3-NP-treated animals followed by administration of formaldehyde dissolved in 0.1 M PB (ϳ50 ml/mouse) hMSCs). For 9 days, 16-week-old male C57BL/6 mice at 30 days after the first injection. Brains were removed were injected with MPTP (10 mg/kg, total dose 90 mg/ from the skulls, postfixed overnight in buffered 4% kg, IP) and 3-NP (10 mg/kg × 4, 20 mg/kg × 4, 30 mg/ paraformaldehyde at 4°C, and stored in a 30% sucrose kg × 4, 40 mg/kg × 4, and 50 mg/kg × 1, total dose 450 solution for 1-2 days at 4°C until they sank. Coronal mg/kg; 12-h intervals; IP) (5). Control mice were insections (30 µm) were obtained and stored in tissue jected with saline alone using the same administration stock solution (30% glycerol, 30% ethylene glycol, 30% schedule and method. One day after the last injection, 3× distilled water, 10% 0.2 M PB) at 4°C until use. For hMSCs were injected into the tail vein (1 × 10 6 cells/ Western blotting, the mice were euthanized 30 days after 200 µl). After the last drug injection, MPTP + 3-NP mice the first injection of double toxins, and the SN and striashowed 36% mortality and we chose hMSC-injected tum were rapidly dissected from the brains and frozen group randomly from live mice. Behavioral (n = 8/ at −70°C. group), histopathological (n = 5/group), and Western blot analyses (n = 3/group) were performed randomly Immunohistochemistry among three groups of mice. Animal experimental pro-
The 30-µm coronal brain sections were rinsed twice tocols were approved by the Ajou University Instituin PBS and incubated in 0.2% Triton X-100 for 30 min tional Animal Care and Use Committee.
at room temperature (RT). They were rinsed three times Isolation of hMSCs and blocked with 0.5% bovine serum albumin (BSA) in 1× PBS. After blocking, sections were incubated at 4°C Bone marrow aspirates (10 ml) were obtained from the iliac crests of human donors. The mononuclear cell overnight with the following primary antibodies: mouse anti-tyrosine hydroxylase (TH; 1:2000; Pel-freez, Rog-layer was isolated by Ficoll-Hypaque, washed with PBS, and plated in polystyrene 100-mm culture dishes. Cells ers, AR, USA), mouse anti-NeuN (1:500; Chemicon, Billerica, MA, USA), mouse anti-nuclear matrix (NuMA; were maintained in low-glucose Dulbecco modified Eagle's medium (DMEM; Gibco-BRL, Grand Island, NY, 1:100; Calbiochem, San Diego, CA, USA), mouse anticalbindin-D-28K (Cal; 1:3000; Sigma-Aldrich, St. USA) containing 10% fetal bovine serum (FBS; Hyclone, Louis, MO, USA), rabbit anti-Iba-1 (1:1000; Wako, ing covered the entire SN and striatum from the rostral tip of the pars compacta back to the caudal end of the Richmond, VA, USA), and rabbit anti-GFAP (1:1000; Chemicon, San Diego, CA, USA). Following overnight pars reticulate. This generally yielded eight to nine sections in a series. Sampling was performed using an incubation, the brain sections were rinsed three times with 0.5% BSA in 1× PBS (10 min/rinse) and incubated Olympus BX51 microscope in conjunction with the Olympus CAST-Grid system (Olympus Denmark A/S, with the appropriate biotinylated secondary antibody and avidin-biotin complex (Elite Kit; Vector Labora-Denmark), which was connected to the stage. Information regarding the z-axis distance was defined in the tories, Burlingame, CA, USA) for 1 h at RT. Bound antibodies were visualized by incubating the sections software. The SN and striatum were delineated at 1.25× objective. A counting frame (60%, 35,650 µm 2 ) was with 0.05% diaminobenzidine-HCl (DAB) and 0.003% hydrogen peroxide in 0.1 M PB. The brain sections were placed randomly on the first counting area and systematically moved though all counting areas until the entire rinsed with 0.1 M PB for DAB inhibition. Immunostained cells were analyzed by bright-field microscopy.
delineated area was sampled. Actual counting was performed using a 40× oil objective. Guard volumes (i.e., Western Blot Analysis 4 µm from the top and 4-6 µm from the bottom of the section) were excluded from both surfaces to avoid the Brain regions of the striatum and SN were dissected and homogenized in ice-cold lysis buffer (20 mM Tris-problem of lost cap, and only the profiles that came into focus within the counting volume (with a depth of 10 HCl, pH 7.5, 1 mM EDTA, 5 mM MgCl 2 , 1 mM dithiothretol, 0.1 mM phenylmethylsulfonyl fluoride plus pro-µm) were counted. The total number of stained cells was calculated according to the optical fractionator formula tease inhibitor cocktail; Sigma-Aldrich). Tissue homogenate was centrifuged (14,000 × g, 20 min, 4°C), and (31). supernatant was transferred into fresh tubes. Proteins were analyzed using the Bio-Rad Protein Assay Kit Statistical Analysis (Bio-Rad, Hercules, CA, USA). Equal amounts of pro-Comparisons between groups were made using the tein (i.e., 50 µg) were loaded in each lane with loading Student t-test (paired) or one-way analysis of variance buffer containing 0.125 M Tris-HCl, pH 6.8, 20% glyc-(ANOVA, nonparametric) followed by a Dunnet post erol, 4% SDS, 10% mercaptoethanol, and 0.002% brohoc test. Values of p < 0.05 were considered statistically mophenol blue. Samples were boiled for 5 min before significant. Data were expressed mean ± SD. Statistical gel loading. Proteins were transferred electrophoretically analyses were performed using commercially available to polyvinylidiene difluoride membranes (Millipore, Besoftware (version 10.0; SPSS Inc., Chicago, IL, USA). dford, MA, USA). Membranes were washed in Trisbuffered saline solution with 2.5 mM EDTA (TNE) and RESULT then blocked in TNE containing 5% skim milk for 1 h. Membranes were incubated overnight at 4°C with the Characterization of hMSCs following primary antibodies: Akt, p-Akt, cytochrome C Fluorescence-activated cell sorting analysis con-(1:1000; Cell Signaling, Danvers, MA, USA), Bax, firmed that hMSCs expressed CD105 and CD73, posi-BCL-2 (1:1000; Stressgene, Ann Arbor, MI, USA), and tive markers for hMSCs. Furthermore, hMSCs did not β-actin (1:500; Imgenex, San Diego, USA). After washexpress CD45 and CD34, negative markers for hMSCs ing, the membranes were incubated with secondary anti- (Fig. 1A) . Immunofluorescent labeling showed that hMbodies (1:2000; Amersham, Piscataway, NJ, USA) for 1 SCs were positive for CD105 and negative for CD34 h at RT and washed again. The blots were finally devel- (Fig. 1B) . oped with ECL Western blotting detection reagents (Amersham). For semiquantitative analysis, the densities significantly increased in double-toxin-induced MSA-P Stereological Cell Counts mice compared with the control group (p < 0.005) (Fig.  2) . Compared with the double-toxin treatment alone, Total SN and striatum cell number was estimated using an optical fractionator and unbiased stereology of hMSC administration in double-toxin-treated mice resulted in a significant decrease in the total time to de-stained cells, as previously described, with some modifications (12) . This sampling technique is not affected by scend the pole. This significant difference was maintained for 10 days after hMSC administration (p < 0.05) tissue volume changes and does not require reference volume determination (31). The sections used for count- (Fig. 2) . 
Detection of hMSCs in the SN and Striatum Histological Analysis of Administrated hMSCs in the Double-Toxin-Induced MSA-P Model of Double-Toxin-Treated Mice
To determine whether transplanted hMSCs survived, Brain tissue was prepared for immunohistochemical analysis 4 weeks after the first MPTP and 3-NP coinjec-we attempted to identify hMSCs in the SN and stratum in double-toxin-treated mice using human-specific NuMA tions. Immunohistochemical analysis showed that administration of both toxins induced a significant decline immunostaining. In controls and in animals treated with double toxins alone, there were no NuMA-ir cells in the in the number of TH-ir cells in the SN and NeuN-ir cells in the striatum (Fig. 4A ). Neuronal loss, as quantified SN and striatum (Fig. 3A, B) . In contrast, NuMA-ir cells were observed following hMSC administration in dou-by stereological analysis, revealed that TH-ir and NeuNir cells decreased by approximately 48% and 29%, re-ble-toxin-treated mice (Fig. 3A) , and the number of NuMA-ir cells in the SN (20,120 ± 825) and striatum spectively (both p < 0.001) (Fig. 4B ). However, hMSC administration significantly reduced neuronal loss in the (37,859 ± 25) corresponded to about 2.0% and 3.8% of a total of 1 × 10 6 injected hMSCs (Fig. 3B) .
double-toxin-treated SN and striatum (Fig. 4A ). Stereo- Figure 2 . Motor behavior testing. The total time it took a mouse to descend a pole and place all four paws on the floor was significantly increased in double-toxin-treated mice compared with controls (n = 8; p < 005). Compared with double-toxin treatment alone, hMSC administration in double-toxin-treated mice significantly decreased the total descent time; this significant difference was maintained for 10 days after hMSC administration (n = 8; *p < 0.05). logical analysis revealed that the number of TH-ir and MPTP and 3-NP treatment in the SN and striatum with coincident improvement in motor behavior. Neuropro-NeuN-ir cells was significantly greater in the hMSCtreated group than in the MPTP + 3-NP-treated group, tective mechanisms exerted by hMSCs may be mediated by modulation of inflammatory and cell survival and showing a 23% and 18% increase in the survival of THir and NeuN-ir cells in the SN and striatum, respectively death signaling-pathway as the hMSCs migrated from the peripheral circulation into the SN and striatum. (p < 0.05) ( Fig 4B) . To evaluate functional neurons, cells in the SN and striatum were immunostained with With advances in the understanding of MSA pathobiologies, it has been suggested that oligodendroglial Calbindin-D-28kD, a marker for calcium binding protein, which is important to maintain in synaptic trans-degeneration resulting from α-synuclein inclusion formation contributes to secondary widespread neuronal mission and axonal transport. Consistent with the increase of neuronal survival in the SN and striatum of degeneration. However, the initial trigger or aggravating mechanism underlying the abnormal accumulation and double-toxin-treated mice after hMSC administration, the number of Calbindin-D-ir cells in the SN and stria-aggregation of α-synuclein in MSA remains unknown. In case-control epidemiological studies, occupational tum was significantly greater in the hMSC-treated group compared with the double-toxin-treated group (p < 0.05) exposure to pesticides, insecticides, or solvents that interrupt mitochondrial electron transport is associated (Fig. 4C, D) .
with increased risk of MSA (19, 28) . In animal studies,
Effects of hMSC Therapy on Modulation
high-dose 3-NP administration also aggravated nigrostriof Inflammation and Gliosis in Animals atal and olivopontocerebellar degeneration in MSA Exposed to Double Toxins transgenic mice using proteolipid protein promoters (25). Furthermore, we recently reported that 3-NP ad-To determine the effects of hMSCs on modulation of inflammation and gliosis, the SN and striatum were ministration in transgenic mice led to oxidation-specific modifications of α-synuclein that were concomitant with immunostained with Iba-1 and GFAP, markers for activated microglia and activated astrocytes, respectively. A an exacerbation of behavioral deficits and widespread neuronal and oligodendrocytic pathology in a number of marked increase in Iba-1 and GFAP-immunoreactivity was observed in double-toxin-treated mice (Fig. 5) ; hMSC brain regions implicated in MSA (27) . These data support that derangement in mitochondrial function by mi-treatment in double-toxin-treated mice significantly decreased Iba-1 and GFAP immunoreactivity (Fig. 5A, C) .
tochondrial neurotoxins, such as MPTP or 3-NP used in this study, may be a main mediator for progression of Stereological analysis revealed that the number of activated microglia and astrocytes was significantly de-MSA pathology.
Our study demonstrated that hMSCs had neuropro-creased in the SN and striatum of the hMSC-treated group compared with the double-toxin-treated group (p < tective properties against mitochondria-inhibiting double-toxin-induced neuronal cell loss, showing about a 0.01 in microglia, p < 0.001 in astrocytes) ( Fig. 5B, D) .
20% increase in the survival of TH-ir and NeuN-ir cells Effect of hMSCs Treatment on Modulation in the SN and striatum. A significant improvement of of Cell Death Signaling Pathway motor behavior after hMSC treatment was in accordance with increased survival of these neuronal cells following To determine the effects of hMSCs on cell survival and death signaling-pathway modulation, Western blot hMSC treatment in double-toxin-treated mice, although functional recovery was not maintained in the end of the analysis was performed using brain tissue prepared at 4 weeks after the first MPTP and 3-NP coinjections ( Fig. study period possibly due to the effect of spontaneous recovery in double-toxin-only-treated animals. The neu-6A, B). p-Akt expression was significantly reduced in double-toxin-treated mice compared with controls; how-roprotective effects of MSCs seem to be mediated by complex mechanisms. First, our study has demonstrated ever, hMSC administration in double-toxin-treated mice increased the expression of p-Akt. hMSC treatment sig-that hMSCs can restore the balance between neuronal survival and apoptosis, which is disrupted by mitochon-nificantly decreased Bax expression in double-toxintreated mice, whereas the expression of Bcl-2 was sig-drial neurotoxins. In this study, hMSC treatment significantly increased the expression of the cell survival factor nificantly increased in double-toxin-treated mice after hMSC administration. In addition, hMSCs significantly p-Akt in double-toxin-treated mice. p-Akt activation is modulated by growth factors and prevents apoptotic cell decreased the expression of cytochrome c, which was elevated after double-toxin treatment.
death signaling pathways (22) . Although we did not investigate the potential factors that induced pAkt acti-DISCUSSION vation, MSCs are known to increase the production of various neurotrophic factors, such as NGF, BDBF, or The present study revealed that hMSC treatment significantly protected against neuronal loss induced by NT-3 (2,10), which may modulate pAkt activation in this study. Along with upregulation of cell survival sig-In conclusion, we have shown that hMSC treatment has a protective effect against neuronal death induced naling pathways by hMSCs, hMSCs also modulated expression of pro-and antiapoptotic proteins toward by double mitochondrial neurotoxins in the SN and striatum. Modulation of inflammatory actions and cell sur-suppressing apoptotic cell death signaling, and thus prevented the release of cytochrome c from mitochondria.
vival and death signaling pathways by hMSCs may work in the neuroprotective process. To be clinically ap-Second, hMSC treatment had anti-inflammatory and antigliotic effect, showing significantly decreased acti-plicable in patients with MSA, further study to evaluate the long-term beneficial effect of hMSCs using trans-vation of microglia and astrocytes in the double-toxintreated SN and striatum. As in PD, microglial reaction genic mice of MSA is needed. and inflammatory processes also participate in the cas- significantly correlated with the burden of GCI in the extrapyramidal motor and cerebellar input systems (8).
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